Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers.
The stocks founds in the One Hot Stock category use stocks that are in long term, short term trends and are early in the buy signal trend. Suggested buy prices are listed with a price “or better”. Or better means anything lower than the buy price listed. (Learn about order types here). This is a confirmation strategy that waits for the stock to make a move then a trader enters the trend at specific prices. In many cases stocks that are in up trends tend to continue the overall trend direction and the prior trend is the path of least resistance. To learn more about trend following as well as reversal strategies you can go here.
